NVCT
Nuvectis Pharma, Inc.
Price Chart
No historical data available
Latest Quote
$23.06
+0.33 (+1.45%)
Current Price
| Previous Close | $22.73 |
| Open | $22.80 |
| Day High | $23.81 |
| Day Low | $22.77 |
| Volume | 176,908 |
Stock Information
| Shares Outstanding | 32.64M |
| Cash Equivalents | $22.16M |
| Net Income | $-30.27M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $752.77M |
| EPS (TTM) | $-1.32 |
| Exchange | NCM |
Recent Price History
No history data available. Data will be fetched automatically.
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
đ° Latest News
No news articles available at the moment. Check back later for updates on NVCT.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $27,574,000 | $19,847,000 | $22,897,000 | $19,234,000 |
| Net Non Operating Interest Income Expense | $1,132,000 | $847,000 | $637,000 | $149,000 |
| Operating Expense | $27,574,000 | $19,847,000 | $22,897,000 | $19,234,000 |
| General And Administrative Expense | $9,421,000 | $6,929,000 | $7,517,000 | $6,007,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-26,442,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Net Interest Income | $1,132,000 | $847,000 | $637,000 | $149,000 |
| Interest Income | $1,132,000 | $847,000 | $637,000 | $149,000 |
| Normalized Income | $-26,442,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Net Income From Continuing And Discontinued Operation | $-26,442,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Total Operating Income As Reported | $-27,574,000 | $-19,847,000 | $-22,897,000 | $-19,234,000 |
| Net Income Common Stockholders | $-28,871,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Net Income | $-26,442,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Net Income Including Noncontrolling Interests | $-26,442,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Net Income Continuous Operations | $-26,442,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Pretax Income | $-26,442,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Interest Income Non Operating | $1,132,000 | $847,000 | $637,000 | $149,000 |
| Operating Income | $-27,574,000 | $-19,847,000 | $-22,897,000 | $-19,234,000 |
| Per Share | ||||
| Diluted EPS | $-1.32 | $-1.11 | $-1.43 | $-1.51 |
| Basic EPS | $-1.32 | $-1.11 | $-1.43 | $-1.51 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-27,574,000 | $-19,847,000 | $-22,897,000 | $-19,234,000 |
| EBITDA (Bullshit earnings) | $-27,574,000 | $-19,847,000 | $-22,897,000 | $-19,234,000 |
| EBIT | $-27,574,000 | $-19,847,000 | $-22,897,000 | $-19,234,000 |
| Diluted Average Shares | $21,812,716 | $17,113,169 | $15,556,655 | $12,657,651 |
| Basic Average Shares | $21,812,716 | $17,113,169 | $15,556,655 | $12,657,651 |
| Diluted NI Availto Com Stockholders | $-28,871,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Otherunder Preferred Stock Dividend | $2,429,000 | $0 | - | - |
| Research And Development | $18,153,000 | $12,918,000 | $15,380,000 | $13,227,000 |
| Selling General And Administration | $9,421,000 | $6,929,000 | $7,517,000 | $6,007,000 |
| Other Gand A | $6,401,000 | $4,232,000 | $4,377,000 | $3,068,000 |
| Insurance And Claims | $599,000 | $606,000 | $842,000 | $1,183,000 |
| Salaries And Wages | $2,421,000 | $2,091,000 | $2,298,000 | $1,756,000 |
Fetched: 2026-08-29
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $18,413,000 | $9,713,000 | $12,201,000 | $14,219,000 |
| Total Assets | $31,709,000 | $18,607,000 | $19,185,000 | $20,405,000 |
| Total Non Current Assets | $0 | $0 | $0 | $0 |
| Current Assets | $31,709,000 | $18,607,000 | $19,185,000 | $20,405,000 |
| Other Current Assets | $75,000 | $74,000 | $59,000 | $412,000 |
| Cash Cash Equivalents And Short Term Investments | $31,634,000 | $18,533,000 | $19,126,000 | $19,993,000 |
| Cash And Cash Equivalents | $31,634,000 | $18,533,000 | $19,126,000 | $19,993,000 |
| Non Current Deferred Assets | - | - | - | $0 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $13,296,000 | $8,894,000 | $6,984,000 | $6,186,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $13,296,000 | $8,894,000 | $6,984,000 | $6,186,000 |
| Payables And Accrued Expenses | $6,389,000 | $3,338,000 | $3,186,000 | $3,805,000 |
| Payables | $6,274,000 | $2,498,000 | $2,771,000 | $3,360,000 |
| Accounts Payable | $6,274,000 | $2,498,000 | $2,771,000 | $2,910,000 |
| Other Payable | - | - | - | $450,000 |
| Equity | ||||
| Common Stock Equity | $18,413,000 | $9,713,000 | $12,201,000 | $14,219,000 |
| Total Equity Gross Minority Interest | $18,413,000 | $9,713,000 | $12,201,000 | $14,219,000 |
| Stockholders Equity | $18,413,000 | $9,713,000 | $12,201,000 | $14,219,000 |
| Retained Earnings | $-99,687,000 | $-73,245,000 | $-54,245,000 | $-31,985,000 |
| Preferred Securities Outside Stock Equity | - | - | - | $0 |
| Other | ||||
| Ordinary Shares Number | $25,676,798 | $19,495,683 | $17,418,886 | $14,642,483 |
| Share Issued | $25,676,798 | $19,495,683 | $17,418,886 | $14,642,483 |
| Tangible Book Value | $18,413,000 | $9,713,000 | $12,201,000 | $14,219,000 |
| Invested Capital | $18,413,000 | $9,713,000 | $12,201,000 | $14,219,000 |
| Working Capital | $18,413,000 | $9,713,000 | $12,201,000 | $14,219,000 |
| Total Capitalization | $18,413,000 | $9,713,000 | $12,201,000 | $14,219,000 |
| Additional Paid In Capital | $118,100,000 | $82,958,000 | $66,446,000 | $46,204,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,907,000 | $5,556,000 | $3,798,000 | $2,381,000 |
| Current Accrued Expenses | $115,000 | $840,000 | $415,000 | $445,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-08-29
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-16,009,000 | $-12,247,000 | $-15,954,000 | $-13,559,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-16,009,000 | $-12,247,000 | $-15,954,000 | $-13,559,000 |
| Cash Flow From Continuing Operating Activities | $-16,009,000 | $-12,247,000 | $-15,954,000 | $-13,559,000 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $0 | $0 | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $31,210,000 | $12,036,000 | $5,289,000 | $31,879,000 |
| Financing Cash Flow | $29,110,000 | $11,654,000 | $15,087,000 | $27,810,000 |
| Cash Flow From Continuing Financing Activities | $29,110,000 | $11,654,000 | $15,087,000 | $27,810,000 |
| Net Other Financing Charges | $-2,100,000 | $-382,000 | $-1,394,000 | $-4,069,000 |
| Net Common Stock Issuance | $31,210,000 | $12,036,000 | $5,289,000 | $31,879,000 |
| Common Stock Issuance | $31,210,000 | $12,036,000 | $5,289,000 | $31,879,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $31,634,000 | $18,533,000 | $19,126,000 | $19,993,000 |
| Beginning Cash Position | $18,533,000 | $19,126,000 | $19,993,000 | $5,742,000 |
| Changes In Cash | $13,101,000 | $-593,000 | $-867,000 | $14,251,000 |
| Change In Working Capital | $4,401,000 | $1,895,000 | $1,601,000 | $3,819,000 |
| Change In Other Working Capital | $1,351,000 | $1,758,000 | $1,417,000 | $1,951,000 |
| Change In Other Current Assets | $-1,000 | $-15,000 | $353,000 | $-321,000 |
| Change In Payables And Accrued Expense | $3,051,000 | $152,000 | $1,248,000 | $4,140,000 |
| Change In Accrued Expense | $-725,000 | $425,000 | $1,387,000 | $2,289,000 |
| Change In Payable | $3,776,000 | $-273,000 | $-139,000 | $1,851,000 |
| Change In Account Payable | $3,776,000 | $-273,000 | $-139,000 | $1,851,000 |
| Stock Based Compensation | $6,032,000 | $4,858,000 | $4,705,000 | $1,707,000 |
| Net Income From Continuing Operations | $-26,442,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Proceeds From Stock Option Exercised | - | $0 | $11,192,000 | $0 |
| Interest Paid Supplemental Data | - | - | - | - |
| Income Tax Paid Supplemental Data | - | - | - | - |
Fetched: 2026-08-29